A recombinant soluble form of human FcTRII (rsFcTRII) was genetically engineered by the insertion of a termination codon 5' of sequences encoding the transmembrane domain of a human FcTRII eDNA. Chinese hamster ovary cells were transfected with the modified cDNA and the secreted rsFcTRII purified from the tissue culture supernatant (to >95%, assessed by SDS-PAGE) using heat aggregated human immunoglobulin G (IgG) immunoaffinity chromatography. The IgG-purified rsFcTRII was relatively homogeneous (•31,000 Me) whereas the total unpurified rsFcTRII secreted into the tissue culture supernatant was heterogeneous relating to N-linked glycosylation differences. Functional in vitro activity of the rsFcTRII was demonstrated by: (a) ability to bind via the Fc portion of human IgG and mouse IgG (IgG2a>IgGl>>IgG2b); (b) complete inhibition of binding of erythrocytes sensitized with rabbit IgG to membrane-bound FcTRII on K562 cells; and (c) inhibition of the anti-Leu4-induced T cell proliferation assay. Blood dearance and biodistribution studies show the rsFcTRII was excreted predominantly through the kidney in a biphasic manner, with an or-phase (tl/2 '~25 min) and a r-phase (tl/2 '~4.6 h); the kidneys were the only organs noted with tissue-specific accumulation. In vivo, the administration of rsFc~RII significantly inhibited the immune complex-mediated inflammatory response induced by the reversed passive Arthus reaction model in rats. There was a specific and dose-dependent relationship between the amount of rsFcTRII administered, and the reduction in the size and severity of the macroscopic inflammatory lesion. Histological analysis of the skin showed a diffuse neutrophil infiltrate in both control and rsFcTRII-treated rats, however the perivascular infiltrate and the red cell extravasation was less intense in the rsFc~RII-treated group. It is likely that complement activation leads to neutrophil chemotaxis, but neutrophil activation via FcyRII, which results in inflammatory mediator release, is inhibited. The data indicate that rsFcyRII is a potential therapeutic agent for the treatment of antibody or immune complex-mediated tissue damage.
Summary
A recombinant soluble form of human FcTRII (rsFcTRII) was genetically engineered by the insertion of a termination codon 5' of sequences encoding the transmembrane domain of a human FcTRII eDNA. Chinese hamster ovary cells were transfected with the modified cDNA and the secreted rsFcTRII purified from the tissue culture supernatant (to >95%, assessed by SDS-PAGE) using heat aggregated human immunoglobulin G (IgG) immunoaffinity chromatography. The IgG-purified rsFcTRII was relatively homogeneous (•31,000 Me) whereas the total unpurified rsFcTRII secreted into the tissue culture supernatant was heterogeneous relating to N-linked glycosylation differences. Functional in vitro activity of the rsFcTRII was demonstrated by: (a) ability to bind via the Fc portion of human IgG and mouse IgG (IgG2a>IgGl>>IgG2b); (b) complete inhibition of binding of erythrocytes sensitized with rabbit IgG to membrane-bound FcTRII on K562 cells; and (c) inhibition of the anti-Leu4-induced T cell proliferation assay. Blood dearance and biodistribution studies show the rsFcTRII was excreted predominantly through the kidney in a biphasic manner, with an or-phase (tl/2 '~25 min) and a r-phase (tl/2 '~4.6 h); the kidneys were the only organs noted with tissue-specific accumulation. In vivo, the administration of rsFc~RII significantly inhibited the immune complex-mediated inflammatory response induced by the reversed passive Arthus reaction model in rats. There was a specific and dose-dependent relationship between the amount of rsFcTRII administered, and the reduction in the size and severity of the macroscopic inflammatory lesion. Histological analysis of the skin showed a diffuse neutrophil infiltrate in both control and rsFcTRII-treated rats, however the perivascular infiltrate and the red cell extravasation was less intense in the rsFc~RII-treated group. It is likely that complement activation leads to neutrophil chemotaxis, but neutrophil activation via FcyRII, which results in inflammatory mediator release, is inhibited. The data indicate that rsFcyRII is a potential therapeutic agent for the treatment of antibody or immune complex-mediated tissue damage.
F
e receptors for IgG (FcTR) exist in two forms: membranebound FcTR and soluble FcTR (sFcTR) 1 which circulate in biological fluids. The two forms of Fc~Rs have been described in both human and murine systems, and have a central role in the regulation of the immune response (1) . Membrane-bound human FcTRs are widely expressed on hemopoietic cells and can be divided into three major classes on the basis of their structure and affinity for IgG: FcyRI, FcyRII, and FcTRIII (2, 3) . FcTRs are important signal transduction molecules, and the interaction of immune complexes 1 Abbreviations used in this paper: CHO, Chinese hamster ovary; EA, sheep red blood cell sensitized with rabbit IgG; HAGG, heat aggregated human lgG; MSX, l.-methionine sulphoxamine; R.PAR, reversed passive Arthus reaction; sFcTR, soluble receptor for the constant region of IgG.
through the Fc portion of IgG or mAbs with cell surface FcTRs triggers the activation of monocytes, neutrophils, and platelets (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) . The binding of immune-complexes to monocytes and neutrophils stimulates the release of inflammatory mediators such as leukotrienes, prostaglandins, and cytokines (TNF-a, IL-1, and IL-6), inducing tissue damage (16) (17) (18) (19) (20) (21) (22) . Although the exact role of the Fc~R(s) in mediating each of these effects has not been fully determined, human FcTRII has been definitively shown to signal immune complex-mediated activation of neutrophils and monocytes. In addition, platelets interact with immune complexes by cell surface FcTRII (the only FcTR expressed on platelets), leading to the secretion of mediators and platelet aggregation (8) (9) (10) (11) (12) (13) (14) (15) .
Endogenous and recombinant sFcyR have been shown to have both in vitro and in vivo immunoregulatory activity and functional properties (23) (24) (25) (26) (27) (28) (29) (30) (31) (32) . In vitro, endogenous sFcyR are released from cells expressing membrane-bound Fc~rR: activated T cells, B cells, macrophages, monocytes, and granulocytes (33) (34) (35) (36) (37) (38) (39) . Soluble Fc'yR can be released by proteolysis of membrane-bound Fc'yR. (28, 29, 33) , or possibly by alternative RNA splicing of the transmembrane exon (40) , and can be stimulated by Ig and cytokines (1) . Endogenous mouse sFc'yR has a relative molecular mass of 35-40 kD and reacts with an anti-mouse Fc'yRII mAb, 2.4G2. This antigenic similarity provides further evidence that endogenous sFcyRII and membrane-bound FcyRII are structurally related (41) . In vitro, murine sFc'yRII can modulate the immune response by inhibition of four separate pathways: (a) binding of immune complexes to cell surface Fc'yRII; (b) Clq binding to IgG; (c) B cell growth; and (d) IgG and IgM antibody production from B cells (1, (23) (24) (25) (26) (27) (28) (29) . Endogenous murine sFc3,RII can be detected in serum of normal mice, and is elevated in states of altered immunity and tumor-bearing mice, indicating it may have an important biological role in vivo (36, (42) (43) (44) (45) (46) . Supporting this concept, murine recombinant sFc'yRII has been demonstrated to inhibit the in vivo IgG response in mice (29) . Similarly in humans, sFyRIII can be detected in vivo from serum of normal individuals and patients with autoimmune diseases, and at sites of inflammation (47) (48) (49) . The immunosuppressive properties of sFc3"RII and its potential ability to inhibit membrane-bound Fc'yRIImediated cellular activation by immune complexes, opens new therapeutic pathways for the treatment of antibody or immune complex-mediated tissue injury. This study describes the production, characterization, in vitro and in vivo activity of a human rsFcyRII.
Materials and Methods
Genetic Engineering and Production of rsFcTRIL Using the PCR, cDNA for a truncated soluble form of human Fc3,RII was produced by inserting a premature termination codon 5' of the transmembrane domain of a membrane-bound FcyRII cDNA (HFc3.0) (50) . The HFc3.0 cDNA encodes the Fc3,RIIa allelic variant expressing glutamine and histidine at amino acid positions 27 and 131, respectively. The oligonucleotide primers used in the PCR were 5' oligonucleotide, NR1 (5'TACGAATTCCTATGGAGA-CCCAAATGTCTCY), and 3' oligonucleotide, F12 (5'CATTCT-AGACTATTGGACAGTGATGGTCAC3'). Both oligonucleotide primers were phosphorylated (100 ng primer, 2/zl 10 mM ATP, 50 mM Tris-HC1, pH 7.6, 10 mM MgCh, 5 mM dithiothreitol, 0.1 mM EDTA, 80 U polynucleotide kinase [Pharmacia, Uppsala, Sweden], in 200/zl, incubated for 1 h at 37~ and used to amplify the mutated cDNA (100 ng of membrane-bound Fc'yR.II cDNA HFc3.0, 500 ng of primers, 50 mM KC1, 10 mM Tris-HC1, pH 8.3, 1.5 mM MgCI2, and 2.5 U Replinase [Dupont, Boston, MA D with a 30 cycle PCR. The oligonucleotide F12 converted the Va1171 codon to a TAG stop codon in the HFc3.0 amplified cDNA, resulting in a 635-bp blunt-ended nucleotide fragment, which was ligated into the Sinai restriction site of the linearized dephosphorylated pEE6/HCMWGS eukaryotic expression vector (Celltech, Slough, England). The plasmid construct was transfected into Chinese hamster ovary (CHO) cells using the calcium phosphate precipitation method (51, 52) lmmunoafllnity Purification tithe rsFcTRlI. Cell culture supernatant containing the rsFc3,RII was passed through a 0.2-#m filter and the sample was loaded onto an af~nity column containing heat aggregated human IgG (HAGG) coupled to Sepharose 4B beads (Pharmacia). To produce this column, 10 mg of HAGG per 1 g of CNBr-activated freeze-dried powder was coupled according to the manufacturer's guidelines (Pharmacia). HAGG was prepared by heating 6 mg/ml of human IgG (Sandoz, Melbourne, Australia) to 63~ for 30 rain. After washing the column with PBS, the bound rsFe,/RII was ehted with a 0.1 M acetate buffer, pH 4.0, containing 0.5 M NaC1. The eluant was immediately neutralized with saturated Tris-HCl and dialyzed against PBS. The molecular weight and purity of the rsFc~/RII were determined by SDS-PAGE analysis. The protein content of the purified samples was determined by absorbance at 280 nm using an extinction coefficient of el% = 22 for a 1 mg/ml protein solution calculated from an amino acid analysis of the rsFc3,RII. The purification was carried out at 4~ and the purified protein stored frozen at -70~ in PBS. Samples were examined for the presence of endotoxin using the Multi-Test Limulus Amebocyte Lysate Pyrogent (Whittaker Bioproducts, Walkersville, MD).
Biosynthetic Labeling and Deglycosylation of the rsFcyRiI. Deglycosylated recombinant protein was produced by adding 5/zg/ml tunicamycin (Sigma Chemical Co.) to the secreting transfected CHO cells for 2 h at 37~ control transfected ceils were grown in the absence of tunicamycin. Both control and tunicamycin-treated cells were pulsed for 2 h with 0.5 mCi of [3SS]methionine and [35S]cysteine (Amersham International, Amersham, UK) in glutamine/methionine/cysteine free medium (Select-Amine; GIBCO BRL, Gaithersburg, MD) followed by a 2-h incubation in the presence of 100-fold excess cold methionine/cysteine. Metabolically labeled supernatants from tunicamycin-treated and untreated transfected ceils were precleared for 30 rain at 4~ with packed Sepharose 4B beads coupled to protein A (Pharmacia) and immunoprecipitation (using 1 ml of radiolabeled supernatant per mAb) carried out for 1 h at 4~ with 30 #1 of packed Sepharose 4B beads conjugated to the following mAbs: (a) anti-Fc3,RII mAbs, 8.26 F(ab'), 8.2 F(ab')2, 8.7 F(ab')2, IV.3 F(ab'), and CIKM5 F(ab')2, and a control mAb, 1705 (5084-4.1) F(ab')2, were used with supernatant from transfected ceils grown in the absence of tunicamycin; and (b) mAb 8.26 was used to immunoprecipitate from supernatant harvested from transfected CHO cells treated with tunicamycin (53) (54) (55) (56) . The beads were washed with a buffer containing PBS, 1% BSA, I mM PMSF, and 0.1% vol/vol aprotinin, pH 7.4 (Sigma Chemical Co.), placed in 20/zl of SDS-PAGE sample buffer (0.1 M Tris-HC1, pH 7.5, 0.1% SDS, 0.1 M dithiothreitol), boiled for 5 min, analyzed by SDS-PAGE on a 13% gel which was dried and autoradiographed.
ImmunoprecipitationandSDS-PAGEAnalysis. Purified rsFc'yRII (100 #g) was radiolabeled with 12sI (Amersham International) using chloramine T (57). The rsF~KII was diluted to 0.2 #g/ml in a buffer containing PBS, 1% BSA, 1 mM PMSF, and 0.1% vol/vol aprotinin, pH 7.4, precleared, and immunoprecipitation (0.2/~g of labeled rsFc3~RII per antibody) was carried out as described above with 30 #1 of packed Sepharose 4B beads conjugated to the following antibodies: (a) anti-human Fc~RII mAb, 
Erythrocytes Sensitized with Rabbit IgG (EAs) Rosetting Inhibition
Assays. The ability of the rsFc3/RII to block the binding immune complexes to membrane-bound Fc~RII was determined by the inhibition of EA rosette formation. Starting at a final concentration of 0.4 mg/ml, doubling dilutions of the purified rsFc~/RII or a control protein, OVA, were incubated with 50 #1 of freshly prepared 2% EA (rabbit anti-sheep red cell polyclonal antibody diluted 1:50 bound to sheep red cells) for 1 h on ice (61) . K562 cells (25 #1 at 5 x 106 ceils/ml) expressing Fc~cKII were added to the EAs and rsFc3,RII, incubated for 5 rain at 37~ spun at 200 g for 3 rain, and the pelleted ceils incubated for 30 min on ice. Cells were stained with 0.1% ethyl violet and a typical field of 100 cells was assessed for rosette formation (at least five red cells or 50% of the target cell covered).
Inhibition of the Anti-Leu4-induced T Cell Proliferation Assay by rsFc'yRII. In this assay, T cells coated with anti-CD3 antibody
can be cross-linked via the Fc portion, by the Fc'yR on monocytes (62, 63) . This phenomenon can be inhibited by rsF3~RII. PBMC from an individual were isolated using a Ficoll density gradient (Pharmacia), harvested, washed, and resuspended in RPMI 1640 (Flow Laboratories) supplemented with 10% heat inactivated FCS, 100 U/ml penicillin, 100/~g/ml streptomycin, 2 mM glutamine (Commonwealth Serum Laboratories) and 0.05 mM 2-ME (KockLight Ltd., Suffolk, UK) at 5 x 106 cells/ml. Cells (100/A vol) were aliquoted into U-bottomed sterile 96-well microtiter plates (Nunc, Roskilde, Denmark) and incubated with 50/A of anti-Leu4 (Becton Dickinson & Co., Mountain View, CA) at 1:1,000 dilution and 50 #1 of serially diluted rsFc~RII or control protein, OVA, starting at 1.0 mg/ml final concentration. Incubation was carried out for 72 h at 37~ and over the last 14 h cells were pulsed with 1 /zCi/well [~H]tbymidine (3,000 Ci/mol, Amersham International). Cells were harvested onto glass paper discs and incorporation of [3H]thymidine measured by liquid scintillation counting. It should be noted that the anti-CD3 (murine IgG1)-induced T cell response is characterized by a polymorphism with high and low responses (62, 63) . A high response individual was used in this study.
Blood Clearance and Biodistn'bution Studies in Mice. BALB/c mice
were used to estimate the in vivo half-Life of the rsFc3tKII and the tissue distribution after an intravenous dose. Purified rsFc3/KII (100 #g) was radiolabeled with 12sI using chloramine T (57) and free 12sI removed using PD-IO sephadex column (Pharmacia) (<5% free 12sI was present as shown by TCA protein precipitation). Groups of four mice were injected intravenously with radiolabeled rsFeyKII and were subsequently killed at various time points collecting blood, urine, and tissues; each sample was measured for radioactivity expressed as cpm. For the blood clearance study, the blood volume was calculated as 7% of the body weight and the half-life of the rsFc3,RII obtained from a logarithmic plot of percent injected dose versus time, where tl/2 = In 2/gradient (64) . Radioactivity in the urine was expressed as percent injected dose/ml of urine, and the organs as percent injected dose/gram of tissue.
Arthus Reaction. A modified reversed passive Arthus reaction (RPAR) model (65) was established using 4-6-wk-old SpragueDawley rats (Austin Research Institute) anesthetized with an i.p. injection of 1.5-2.0 ml of a 1.9% 2,2,2-tribromoethanol (Aldrich Chemical Co., Milwaukee, WI) solution. The rats were shaved, and 5 min after a 5 mg i.v. injection of OVA into the tail vein, the back of the rat was injected intradermally with either: (a) 50 /zl of purified rabbit IgG anti-OVA (500/zg) with 50/zl of PBS, positive control (after titration, limiting amounts of rabbit IgG anti-OVA were used to give maximal inhibition, similar to that used elsewhere) (66); (b) 50 #1 of purified nonimmune rabbit lgG (500/~g) with 50 gil of PBS, specificity control; (c) 50/A of rabbit IgG anti-OVA (500 #g) with 50 #1 of rsFc'yRII at varying doses (50-500/~g) or control protein KLH (500/~g) (Sigma Chemical Co.); or (d) rsFc3,KII alone.
Rats were examined at 6 h, and macroscopic skin lesions were analyzed (blind by independent observers) using two criteria: (a) size of the lesion; the area in mm 2 was calculated by multiplying the transverse width in two perpendicular directions; and (b) "total score" reflecting the severity of each lesion; a minor score of 0 (nil), 1 (mild), 2 (moderate), or 3 (severe) was given for two separate parameters (oedema and erythema), and a total score for the lesion was assigned by adding the two minor scores. Skin biopsies at injected sites, taken through the center of the lesion, were fixed in 10% buffered formalin, stained with hematoxylin-eosin (Department of Pathology, Austin Hospital) and examined for edema, polymorphonuclear, and mononuclear cell infiltrate.
StatisticalAnalysis.
A statistical comparison of the size and scores of the rsFeyKII-treated skin and the controls (PBS and KLH treatment) was performed by a one-way analysis of variance (67); p <0.05 was considered significant. (Fig. 1 ) and appears as a "o31,000 M~ band consis- tent with the predicted 20,000 Me of the rsFcyRII polypeptide chain and the extra size from two N-linked carbohydrate structures. The rsFcylklI was >95% pure as analyzed by SDS-PAGE. The stability of the rsFc'yRII in tissue culture supernatant was measured by the ELISA for Fc3,RII, and showed it was stable (mAb epitopes intact) at 4, -20, and -70~ for 6 too. Functional activity of the rsFcyRII, demonstrated by inhibition of EA rosette formation, was completely stable for at least 1 mo at 4~ (data not shown).
Results

Production and
Structure of the Truncated FcTRII. RsFcyRII was deglycosylated to determine the contribution of carbohydrate to the heterogeneity. Cell culture supernatant of clone 1.5 CHO cells biosynthetically labeled with [3SS]methionine and cysteine was used for immunoprecipitation and the molecular weight of the deglycosylated polypeptide determined after growing the transfected CHO cells in tunicamycin. Immunoprecipitation with F(ab') or F(ab')2 fragments of specific anti-human Fcq, RII mAbs demonstrated that the total unpurified rsFcylklI in tissue culture supernatant was heterogeneous with *28,000-36,000 Me (Fig. 2) , whereas the IgG-purified rsFeyR.lI ( Fig. 1 ) was more homogeneous. However, after tunicamycin treatment, a homogeneous ~23,000 Mr band under reducing conditions (Fig. 2) and m21,000 Mr in nonreducing conditions (data not shown) was detected, which agrees with the predicted molecular mass of 20,000 and demonstrated that the heterogeneity of the total rsFc3,RII protein was due to heterogeneity within the N-linked carbohydrate, rather than proteolytic degradation or partial translation of the mlkNA. The five mAbs used (IV.3, CIKM5, 8.2, 8.7, and 8.26) (Fig. 2) previously have been shown to divide into four dusters, each duster defining a separate epitope on the extracellular domains of FeTRII (53) . Cluster 1 (8.2 and CIKMS) defines an epitope with determinants in The murine IgG binding specificity of the rsFc~/KII differs from the membrane-bound human Fc3~KII; rsFcqrKII binds murine IgG2a>IgGl>>IgG2b, and IgG3. It should be noted that the HFc3.0 eDNA encodes a histidine at position 131 and poor immunoprecipitation with the murine IgG1 mAb seen in Fig. 3 would be expected as this is a "low responder" FcyKII (68) (69) (70) . The binding of rsFc3,RII to immune complexes was demonstrated by its ability to inhibit the binding of EAs to cell surface Fc'yKII. Incubation of EAs with rsFeyKII completely inhibited the formation of EA rosettes with K562 cells, with a 50% inhibitory final concentration of 20 #g/ml of purified rsFc3,KII (Fig. 4 A) . In addition, rsFcyRII inhibited the antiLeu4-induced T cell proliferation assay by 50% at a final concentration of 125/zg/ml, indicating the soluble receptor has the capacity to block the binding of immune complexes to Fc3,KII on peripheral blood monocytes (Fig. 4 B) . We also tested the ability of rsEc'yRII to inhibit an antibody-dependent, cell-mediated cytotoxicity assay and a C'-mediated cell lysis assay using rabbit C' and a murine mAb. No inhibition was observed in either assay (data not shown).
In summary, the physical and functional characteristics of the rsFc3,RII are similar to membrane-bound Fc'yKII: (a) rsPc3,RII is structurally related to membrane-bound Fc3,gII as indicated by intact epitopes for the binding of mAbs to membrane-bound Fc3'KII; and (b) rsFc3,KII binds IgG through its Fc region, although the murine isotope binding specificity has been altered compared to membrane-bound human Fc'yKII. It is noteworthy that the general characteristics of human Fc'yKII in relation to binding specificities of IgG have been derived from studies using few cell types and may not apply in all cases (2) .
Blood Clearance and Biodistribution of rsFcT/RII. The in vivo
characteristics of rsFc'yKII were studied in mice by analyzing the blood clearance and biodistribution of intravenously administered t2SI-rsFcTRII. The blood clearance studies demonstrate that t2SI-rsFcTRII is rapidly eliminated from the circulation in a biphasic manner with an or-phase tl/2 of 25 min and a/~-phase tl/2 of 4.6 h; after 24 h the 125I-rsFc3,KII was totally eliminated (Fig. 5 A) . Groups of four mice were also injected intravenously and various organs were counted for radioactivity (Fig. 5 C) . There was a rapid early concentration of 125I-rsFc'yRII in the kidney at 15 rain and 1 h, with a subsequent fall at 6 and 24 h. No other organ exhibited tissue-specific accumulation. The rapid clearance from the circulation, associated with high concentrations in the kidney, suggested the recombinant protein was excreted predominantly through the kidney. Studies of urine demonstrate high levels of It~S-rsFc3~RII at 1 h, indicating this to be the major route of excretion (Fig. 5 B) . The effect of route of administration was studied by giving either an i.p. or i.v. dose of l~5I-rsFc'yKII. An identical pattern of rapid blood dearance was seen with both i.p. and i.v. injections (data not shown).
Inhibition of the Arthus Reaction. Rats given i.v. OVA (5 mg) followed by intradermal rabbit anti-OVA IgG (500 #g) mixed in PBS developed a visible Arthus reaction within 2 h of the intradermal injection and at 6 h were characterized macroscopically by an erythematous and edematous inflamed area of skin measuring 30 mm 2 determined from the width of the lesion in two perpendicular transverse directions (Fig.  6) . Histologically, the tissue section from the site of the lesion showed an inflammatory infiltrate of polymorphonuclear cells, and to a lesser extent mononuclear cells, particularly around venules in the dermis (Fig. 7) . Specifidty of the RPAR was demonstrated by giving rats i.v. OVA, intradermal rabbit IgG, or rsFc3~RII, all given separately to individual rats, or nonimmune rabbit IgG intradermally together with i.v. OVA. In all cases, the RPAR did not develop (data not shown).
To test the effect of rsFc~RII, OVA-injected rats were then given a constant amount of rabbit anti-OVA IgG (500/~g) mixed with rsFcyRII at varying doses (50-500/~g) in a final volume of 100 #1 intradermally. When rsFc3/l~II was given with the rabbit anti-OVA IgG, a specific and significant dosedependent inhibition of the size (using 500/~g of rsFcqrRII, p <0.05) and the score (using 500 and 150 #g of rsFc~RII, Treatment  PBS  PBS  sFc  sFc  sFc  KLH  50Fg 150.u.g 500~g 500gg Figure 6 . Size (/t) and score (B) of the Arthus lesions are shown on the y-axis, using (x-axis): 500/~g of normal rabbit serum (NRS) (n = 7); 500/~g of anti-OVA with PBS (n = 27); 500 #g of anti-OVA with 50 #g of rsFcyKII (sFc) (n = 6); 500/xg of anti-OVA with 150 #g of sFc (n = 8); 500 #g of anti-OVA with 500 ~g of slc (n = 14); and 500/~g of anti-OVA with 500/~g ofKLH (n = 4). (n) Number of injection sites using multiple rats. Error bars represent SE; (*)p <0.05 compared to the PBS-and KLH-treated skin. both p <0.05) of the Arthus lesion was observed, compared to PBS-and KLH (irrelevant protein control) -treated lesions (Fig. 6) . The results represent multiple injections using a number of different rats. Histological sections taken from the sites treated with the rsFcTRII mixed with the rabbit anti-OVA showed a marked reduction in neutrophil accumulation, margination, infiltration around venules, and erythrocyte extravasation compared to PBS-treated skin (Figs. 7-9 ). The mild, persistent neutrophil infiltrate in the rsFcTRIItreated skin is likely to be a consequence of the short tl/2 of rsFcyRII and C activation.
Discussion
A functional rsFcTRII protein was made by genetically deleting the transmembrane and cytoplasmic domains of a human FcyRII protein, and using a novel eukaryotic expression system in CHO cells, resulted in the secretion of the rsFcyRII into the tissue culture supernatant, enabling subsequent purification. The recombinant glycoprotein was shown to have in vitro and in vivo activity. The truncated 31-kD recombinant protein containing the two extracellular domains of FcyRIIa could bind human, mouse, and rabbit Ig by their Fc portions, and completely inhibited the binding of immune complexes to cell surface Fc,/RII. The interaction of immune complexes with cell surface FcTRII initiates a number of Fcmediated effector mechanisms including inflammatory responses, and therefore, a dassical model of immune complex disease (the Arthus reaction) was used to investigate the possible in vivo therapeutic properties of the human rsFcTRII. The RPAR was significantly inhibited by rsFcTRII in a dosedependent manner, with less extensive macroscopic lesions and histological inflammatory cell infiltrates demonstrated in treated areas.
The first part of the study addressed the problem of producing large quantities of purified functional rsFc~RII. The mammalian expression vector, pEE6/CMV/GS, was utilized as it gives high levels of expression (51) . In this study, all the original clones did not survive in >15/~M MSX, although amplification of the initial clones using 100-1,000 /xM MSX produced survivors in 100/~M MSX, and a fourfold increase in rsFc,/RII production was noted in the amplified clones (4-8 mg/liter of supernatant). This could be increased by further selection and attention to the culture medium, however the production level sufficed for our studies. Kinetic studies (data not shown) using supernatant and cell lysates from biosynthetically labeled transfected CHO cells was performed to exclude the possibility of a defective secretory mechanism resulting in intraceUular accumulation of rsFc'},KII. These studies demonstrated that the synthesized rsFcTKII first appeared in the tissue culture supernatant within 1 h of the initial [3SS]methionine/cysteine pulse and was totally secreted in 2 h, with no intraceUular accumulation.
RsFcyRII is a functional receptor and clearly binds IgG through the Fc portion, albeit with altered properties compared to the native cell surface Fc3,RII. Membrane-bound human Fc3,RIIa is a low affinity receptor (K~ = 106 M-1) for monomeric IgG, and the low responder form binds murine IgG2b>>IgG2a,IgG3 compared to rsFcyRII which binds murine IgG2a>IgGl>>IgG2b, or IgG3 (Fig. 3) . The poor binding ofrsFcyKII to murine IgG1 is consistent with the "low responder" phenotype which is a genetically determined polymorphism resulting in the expression of two allelic variants which differ in their ability to bind murine IgG1; high responders bind murine IgG1 more avidly than low responders (62, 63) . Low responder Fc'yRII, like HFc3.0 used herein, contains histidine at position 131 whereas high responder FcyRII contains arginine in this position (68) (69) (70) . Furthermore, some changes in fine specificity may not be unexpected since significant changes in carbohydrate side chains from the native receptor could alter the conformation and therefore the binding properties, as reported for other receptors (71) . This may account for the difference in IgG2a and IgG2b binding reported here and in the literature. The absence of the transmembrane and cytoplasmic tail may also influence structural and functional aspects of the soluble receptor, however, the essential properties have been maintained since the rsFc'i, KII binds IgG via the Fc portion and is recognized by mAbs which detect conformational changes in cell surface Fc3,RII. KsFcyKII is a relatively small polypeptide (31,000 Mr) with '025% of its molecular mass attributable to N-linked glycosylation. Small molecular weight compounds would be expected to be easily filtered through the glomerulus and indeed, the rsFc3,RII is rapidly cleared from the circulation through the kidneys (Fig. 5) . One might expect a longer in vivo half-life if rsFc3~KII bound to IgG in serum, however several factors may influence this interaction: (a) rapid renal clearance not allowing the rsFc3,KII-IgG interaction to approach equilibrium in serum; and (b) affinity of monomeric IgG for rsFc3'RII. The short half-life of the rsFeyRII in vivo will clearly limit the use of the protein as a parenterally administered therapeutic agent, but in its present form, could be useful for local therapy such as in inflamed joints in rheumatoid arthritis. The R.PAR model used in this study produced a localized area of dermal inflammation and demonstrates that rsFeyRII administered concomitantly with anti-OVA antibody significantly reduces the immune complex-mediated tissue damage. Many cytokines with rapid clearance from the circulation, resulting in short-lived pharmacological effects, have been successfully modified to increase their half-life and subsequent potency of the compound in vivo (72) (73) . A similar approach with the rsFeyKII protein (currently in progress) would broaden its therapeutic application to a parenterally administered reagent.
In two other reports (66, 74) C' regulating proteins (soluble C receptor type I and decay accelerating factor) did not completely inhibit the Arthus reaction. In one study, the RPAK model used was similar to that used here (66) . The persisting inflammatory response seen after treatment with the C' regulators is likely to be due to "unblocked" FcyR-mediated inflammatory response. Similarly, in the study described herein, inhibition of the inflammatory response was profound but incomplete. This probably relates to the short tl/2 and/or inability to inhibit C activation. Since both Fc3'R-and C'-mediated inflammatory responses are critical in the pathogenesis of immune complex-induced tissue injury, complete inhibition of the inflammatory response presumably requires inhibition of both pathways. Studies are currently in progress to determine the potency of "combined" therapy.
The mode of action of rsFeyKII is not clear but could be mediating the anti-inflammatory response by several different mechanisms. One likely site of inhibition is the activation of neutrophils and monocytes with subsequent release of inflammatory mediators which is known to be fignaled through the interaction of immune complexes with cell surface FcyRII, and we have shown in this study that rsFcyKII completely inhibits the binding of EA immune complexes to cell surface Fc3,RII and furthermore inhibits the antiLeu4-induced T cell proliferation assay which results from the binding of rsFc'yRII to the Fc portion of anti-Leu4 bound to T cells (Fig. 4) . A second possible mechanism is the interruption of the C' cascade known to release many inflammatory proteins (e.g., C5a) which induce chemotaxis and neutrophil activation. Murine soluble FcyRII has been shown to inhibit C'-mediated lysis of SRBC by IgG in vitro (24) . We found that rsFeyKII did not inhibit C'-mediated cell lysis or antibody-dependent cell-mediated killing by mononudear cells. Antibody-dependent cell-mediated lysis is a function of Fc"/RIII, and therefore inhibition by rsFc'lrRII was not expected. It is likely that complement is activated, which leads to neutrophil chemotaxis, but neutrophil activation via Fc3,R.II by immune complexes, which results in inflammatory mediator release, is inhibited. Platelets have been shown to initiate or augment immunologically mediated inflammation and tissue injury by the activation of circulating platelets through the interaction of immune complexes with cell surface Fc3,RII (8) . Inhibition of platelet activation and aggregation could also reduce the inflammatory response, and we are currently investigating the role of rsFc3,KII in modifying platelet function.
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